La chaîne d'options affiche les données clés des options sur actions de Precision BioSciences à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Precision BioSciences..

Precision BioSciences (NASDAQ:DTIL) Stock, Chaîne d'Options

PRECISION BIOSCIENCES INC

Precision BioSciences

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Wall Street is basking in record highs as the S&amp;P 500 breaks above 6,300 ahead of the July 4 holiday, but just as traders reach for the champagne, a popular market indicator is <a href="https://www.benzinga.com/trading-ideas/technicals">starting to flash red.</a>
<h2 class="wp-block-heading">S&amp;P 500&#8217;s RSI Enters Overbought Territory: Why It Matters</h2>
The S&amp;P 500&#8217;s 14-day Relative Strength Index (RSI), a momentum oscillator that measures the speed and magnitude of price movements, surged to 75.62 on Wednesday, well into the overbought zone above 70.
The RSI ranges from 0 to 100, and traders use it to gauge whether an asset is overbought or oversold. While it doesn&#8217;t predict direction, history shows it often coincides with key market turning points.
In fact, in several recent cases where the S&amp;P 500's RSI hit similarly overbought levels, the index was soon met with sharp and swift pullbacks.
<ul class="wp-block-list">
<li>July 2024: RSI spiked above 75, and the index dropped 10% from 5,660 to August 6</li>
<li>July 2023: RSI flagged overbought, and the S&amp;P 500 slid 10% through late October</li>
<li>September 2020: RSI hit 83 before a rapid 10% decline that same month. </li>
<li>January 2018: RSI hit climbed to 86 after a 7% rally. The index then plunged 12% in just nine trading days during early February.</li>
</ul>
Still, the RSI is not a crystal ball.
In December 2023, the indicator was also overbought, but the S&amp;P 500 – as tracked by the Vanguard S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – kept climbing and added over 15% until April 2024.
Similarly, in December 2019, a reading of 78 did little to slow momentum until COVID-19, a rather unpredictable event, caused the market to crash two months later.
While the RSI's track record shows that overbought conditions can precede sharp pullbacks, it's not a guaranteed signal — especially in a market driven by strong momentum, AI optimism, and resilient economic data. Still, with the S&amp;P 500 at record highs and sentiment running hot, traders may want to keep one eye on the technicals as they celebrate the holiday rally.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-1024x529.png" alt="" class="wp-image-972359" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-1536x794.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-2048x1059.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46225431/alphabet-stock-google-analysis-valuations-outlook">This Magnificent 7 Stock Is Absurdly Cheap – It Probably Won&#8217;t Stay That Way For Long </a></li>
</ul>
Photo: Shutterstock

Equities

Broad U.S. Equity ETFs

Technicals

Trading Ideas

ETFs

The S&P 500 Sank 10% The Last Time This Warning Flashed

Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&amp;D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

&nbsp;
While acquired IPR&amp;D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&amp;D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on April&nbsp;25, 2025 excluded the impact of acquired IPR&amp;D and milestones expense that may be incurred beyond the first quarter of 2025. AbbVie&#39;s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&amp;D and milestones expense, is $11.67 - $11.87. AbbVie&#39;s second quarter 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&amp;D and milestones expense, is&nbsp;

News

Guidance

ABBV

AbbVie Expects $823M Acquired IPR&D And Milestones Expense In Q2 2025, Reducing Non-GAAP Diluted EPS By $0.42 To $2.84-$2.88 For Q2 2025;  FY25 Adjusted Diluted EPS Guidance Range, Including The Impact Of Q2 2025 Acquired IPR&D And Milestones Expense, Is $11.67-$11.87

General

REE Automotive Receives Nasdaq Letter Regarding Minimum Bid Price

Investors with a lot of money to spend have taken a bearish stance on DeFi Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DFDV, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for DeFi Development.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $48,000, and 9, calls, for a total amount of $415,876.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $12.5 to $25.0 for DeFi Development over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for DeFi Development's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across DeFi Development's significant trades, within a strike price range of $12.5 to $25.0, over the past month.
<h3>DeFi Development 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751562692_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DFDV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$13.6</td>
<td>$10.3</td>
<td>$10.6</td>
<td>$25.00</td>
<td>$97.0K</td>
<td align="right">121</td>
<td align="right">95</td>
</tr>
<tr>
<td>DFDV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$4.3</td>
<td>$3.9</td>
<td>$4.3</td>
<td>$25.00</td>
<td>$90.3K</td>
<td align="right">962</td>
<td align="right">210</td>
</tr>
<tr>
<td>DFDV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.5</td>
<td>$7.0</td>
<td>$7.5</td>
<td>$25.00</td>
<td>$62.2K</td>
<td align="right">522</td>
<td align="right">377</td>
</tr>
<tr>
<td>DFDV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$17.5</td>
<td>$14.1</td>
<td>$15.0</td>
<td>$25.00</td>
<td>$48.0K</td>
<td align="right">19</td>
<td align="right">32</td>
</tr>
<tr>
<td>DFDV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.5</td>
<td>$6.9</td>
<td>$7.5</td>
<td>$25.00</td>
<td>$35.2K</td>
<td align="right">522</td>
<td align="right">157</td>
</tr>
</tbody>
</table>

<h3>About DeFi Development</h3>
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
Following our analysis of the options activities associated with DeFi Development, we pivot to a closer look at the company's own performance.
<h3>Current Position of DeFi Development</h3>
<ul>
<li>With a volume of 2,047,894, the price of DFDV is up 2.26% at $20.85. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
<h3>Professional Analyst Ratings for DeFi Development</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $45.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $45. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DeFi Development options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

DFDV

Spotlight on DeFi Development: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Adobe.
Looking at options history for Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) we detected 26 trades.
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 57% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $611,973 and 17, calls, for a total amount of $1,338,990.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $540.0 for Adobe over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Adobe stands at 492.36, with a total volume reaching 1,107.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Adobe, situated within the strike price corridor from $250.0 to $540.0, throughout the last 30 days.
<h3>Adobe 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751562687_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.7</td>
<td>$29.6</td>
<td>$30.0</td>
<td>$405.00</td>
<td>$600.0K</td>
<td>265</td>
<td align="right">1</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$18.3</td>
<td>$18.05</td>
<td>$18.3</td>
<td>$370.00</td>
<td>$183.0K</td>
<td>422</td>
<td align="right">142</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.5</td>
<td>$5.85</td>
<td>$5.85</td>
<td>$385.00</td>
<td>$91.2K</td>
<td>464</td>
<td align="right">8</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$28.4</td>
<td>$26.8</td>
<td>$27.71</td>
<td>$360.00</td>
<td>$83.1K</td>
<td>1.1K</td>
<td align="right">30</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$26.0</td>
<td>$25.05</td>
<td>$25.2</td>
<td>$380.00</td>
<td>$70.4K</td>
<td>767</td>
<td align="right">36</td>
</tr>
</tbody>
</table>

<h3>About Adobe</h3>
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
In light of the recent options history for Adobe, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Adobe</h3>
<ul>
<li>Trading volume stands at 2,021,019, with ADBE's price up by 0.62%, positioned at $380.83.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 70 days.</li>
</ul>
<h3>What Analysts Are Saying About Adobe</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $471.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Mizuho has decided to maintain their Outperform rating on Adobe, which currently sits at a price target of $530. 
&#x2A; An analyst from Evercore ISI Group downgraded its action to Outperform with a price target of $475. 
&#x2A; In a cautious move, an analyst from BMO Capital downgraded its rating to Outperform, setting a price target of $450. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Adobe, which currently sits at a price target of $475. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Neutral rating on Adobe with a target price of $425. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Adobe, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ADBE

Adobe Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OKLO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 18 uncommon options trades for Oklo.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 16%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $357,612, and 12 are calls, for a total amount of $525,352.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $60.0 for Oklo over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Oklo's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Oklo's substantial trades, within a strike price spectrum from $40.0 to $60.0 over the preceding 30 days.
<h3>Oklo Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751562681_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/03/25</td>
<td>$3.3</td>
<td>$2.51</td>
<td>$2.97</td>
<td>$55.00</td>
<td>$133.6K</td>
<td>1.8K</td>
<td align="right">458</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$9.4</td>
<td>$9.1</td>
<td>$9.24</td>
<td>$60.00</td>
<td>$95.1K</td>
<td>1.0K</td>
<td align="right">104</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$16.2</td>
<td>$14.9</td>
<td>$15.18</td>
<td>$41.00</td>
<td>$80.8K</td>
<td>260</td>
<td align="right">50</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$15.9</td>
<td>$15.35</td>
<td>$15.95</td>
<td>$40.00</td>
<td>$79.7K</td>
<td>1.1K</td>
<td align="right">62</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$4.95</td>
<td>$4.9</td>
<td>$4.95</td>
<td>$60.00</td>
<td>$49.5K</td>
<td>1.8K</td>
<td align="right">838</td>
</tr>
</tbody>
</table>

<h3>About Oklo</h3>
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
Following our analysis of the options activities associated with Oklo, we pivot to a closer look at the company's own performance.
<h3>Current Position of Oklo</h3>
<ul>
<li>Trading volume stands at 7,745,076, with OKLO's price up by 3.23%, positioned at $52.99.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 40 days.</li>
</ul>
<h3>Professional Analyst Ratings for Oklo</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $73.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Seaport Global has elevated its stance to Buy, setting a new price target at $71. 
&#x2A; An analyst from Wedbush persists with their Outperform rating on Oklo, maintaining a target price of $75. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Oklo with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

OKLO

This Is What Whales Are Betting On Oklo

WIIM

SY stock has given up its prior gain. So-Young International shares were trading higher after the company regained Nasdaq compliance for its closing bid price.

Offerings

QUBT

Quantum Computing Files For Resale Of Up To 14.04M Shares Of Common Stock By The Selling Stockholder

Goldman Sachs analyst Mark Delaney maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and raises the price target from $285 to $315.

Price Target

Analyst Ratings

TSLA

Goldman Sachs Maintains Neutral on Tesla, Raises Price Target to $315

<a href="https://www.bloomberg.com/news/articles/2025-07-03/china-set-to-cancel-part-of-eu-summit-in-latest-strain-on-ties?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-03/china-set-to-cancel-part-of-eu-summit-in-latest-strain-on-ties?embedded-checkout=true</a>

'China Set to Cancel Part of EU Summit in Latest Strain on Ties'- Bloomberg

<h3>Gainers</h3>
<ul>
<li>Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) shares moved upwards by 35.2% to $10.09 during Thursday's regular session. The market value of their outstanding shares is at $260.5 million. </li>
<li>707 Cayman Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JEM#NASDAQ">JEM</a>) stock rose 30.42% to $5.08. The company's market cap stands at $85.4 million. </li>
<li>Fenbo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) shares rose 17.5% to $1.1. The market value of their outstanding shares is at $10.3 million. </li>
<li>Alliance Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AENT#NASDAQ">AENT</a>) shares moved upwards by 15.78% to $5.28. The company's market cap stands at $232.3 million. </li>
<li>Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) shares increased by 15.33% to $1.88. The market value of their outstanding shares is at $160.6 million. </li>
<li>Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) stock rose 13.95% to $0.81. The company's market cap stands at $32.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) shares fell 19.4% to $1.53 during Thursday's regular session. The market value of their outstanding shares is at $4.5 million. </li>
<li>BT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBD#NASDAQ">BTBD</a>) shares fell 17.53% to $1.13. The company's market cap stands at $8.4 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock declined by 17.34% to $0.23. </li>
<li>GreenTree Hospitality Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHG#NYSE">GHG</a>) stock declined by 11.05% to $2.17. The market value of their outstanding shares is at $247.7 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) stock decreased by 10.43% to $4.04. The company's market cap stands at $19.9 million. </li>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) stock declined by 10.22% to $14.19. The company's market cap stands at $212.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AENT

BTBD

EPSM

FEBO

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

MULN

NDLS

UCAR

XELB

XPOF

12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 120.3% to $22.82 during Thursday's regular session. The market value of their outstanding shares is at $5.1 billion. As per the news, the H1 earnings report came out 3 days ago. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares increased by 41.48% to $2.86. The market value of their outstanding shares is at $5.5 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock moved upwards by 31.37% to $1.91. The market value of their outstanding shares is at $181.1 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares rose 31.14% to $1.56. The company's market cap stands at $39.3 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock rose 27.97% to $2.47. The market value of their outstanding shares is at $14.3 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) stock moved upwards by 23.53% to $0.41. The market value of their outstanding shares is at $20.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares declined by 37.9% to $1.33 during Thursday's regular session. The company's market cap stands at $78.4 million. </li>
<li>Jyong Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MENS#NASDAQ">MENS</a>) shares decreased by 17.68% to $7.92. The company's market cap stands at $731.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares decreased by 11.74% to $0.56. The company's market cap stands at $28.4 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock fell 11.34% to $2.75. The company's market cap stands at $9.7 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 10.54% to $2.64. The market value of their outstanding shares is at $5.4 million. </li>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares declined by 10.41% to $2.41. The company's market cap stands at $81.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CGTX

GTBP

JUNS

LIXT

MENS

ONMD

VERO

ZYXI

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) stock rose 23.8% to $7.5 during Thursday's regular session. The market value of their outstanding shares is at $128.3 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock moved upwards by 23.42% to $4.11. The company's market cap stands at $114.5 million. </li>
<li>NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) stock rose 22.83% to $3.12. The company's market cap stands at $197.4 million. </li>
<li>Concorde Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) stock rose 19.04% to $22.19. The company's market cap stands at $416.1 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) stock rose 18.16% to $0.65. The company's market cap stands at $9.9 million. </li>
<li>Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares increased by 17.18% to $10.54. The company's market cap stands at $2.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Air T (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRT#NASDAQ">AIRT</a>) stock decreased by 20.0% to $16.9 during Thursday's regular session. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) stock declined by 9.47% to $0.36. The market value of their outstanding shares is at $24.8 million. </li>
<li>Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) shares fell 9.31% to $21.92. The market value of their outstanding shares is at $313.9 million. The company's, Q3 earnings came out yesterday. </li>
<li>EuroDry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDRY#NASDAQ">EDRY</a>) shares declined by 9.24% to $8.84. The company's market cap stands at $27.5 million. </li>
<li>Clean Energy Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETY#NASDAQ">CETY</a>) stock fell 8.15% to $0.21. The company's market cap stands at $14.5 million. </li>
<li>Pinnacle Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFAI#NASDAQ">PFAI</a>) stock declined by 7.82% to $1.65. The company's market cap stands at $20.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRT

BURU

CETY

CIGL

EDRY

GLXG

HUHU

NPWR

PFAI

SRFM

12 Industrials Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) shares moved upwards by 133.1% to $136.34 during Thursday's regular session. The market value of their outstanding shares is at $354.7 million. </li>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares increased by 51.98% to $1.18. The market value of their outstanding shares is at $120.3 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock rose 27.53% to $0.17. The market value of their outstanding shares is at $13.9 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares moved upwards by 22.84% to $3.28. The company's market cap stands at $19.6 million. </li>
<li>Ascent Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) stock increased by 20.98% to $2.56. The company's market cap stands at $4.0 million. </li>
<li>SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) shares rose 16.27% to $27.44. The market value of their outstanding shares is at $1.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock fell 14.6% to $0.25 during Thursday's regular session. The company's market cap stands at $18.7 million. </li>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares decreased by 12.6% to $0.28. The company's market cap stands at $16.6 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) stock fell 10.13% to $12.87. The market value of their outstanding shares is at $25.0 million. </li>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) stock fell 8.92% to $5.46. The company's market cap stands at $7.6 million. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) shares fell 7.46% to $2.54. The company's market cap stands at $36.3 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock decreased by 6.82% to $8.2. The company's market cap stands at $207.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRE

AIXI

ARBK

ASTI

BMNR

LCFY

MINM

SEDG

WOLF

12 Information Technology Stocks Moving In Thursday's Intraday Session

ClearOne Announces $3 Million Investment
&nbsp;
SALT LAKE CITY – July 03, 2025 – ClearOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>), a global market leader in conferencing, collaboration, and network streaming solutions, announced on June 25, 2025, that it has recently sold $3 million of convertible notes, which represents an investment in the Company.
This investment was made in connection with the Company's ongoing strategic process and in support of its previously disclosed plan to pursue one or more transactions. Along with the investment, ClearOne has implemented a restructuring that will eliminate a portion of its workforce as part of a broader operational scaling initiative. During this process, ClearOne will continue selling and supporting its award-winning products, ensuring partners and customers receive the high-quality products and service they expect, while simultaneously executing the mission the company has been directed to accomplish by its Board to maximize shareholder value.

Contracts

Management

CLRO

ClearOne Secures $3M Investment By Sale Of Convertible Notes; Announces Workforce Restructuring To Support Strategic Growth Initiatives

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count -7 To 425; U.S. Baker Hughes NatGas Rig Count -1 To 108; U.S. Baker Hughes Total Rig Count 539 Vs 547 Prior

Billionaire Mark Cuban is doubling down on his idea that medical school in the U.S. should be tuition-free. &#8220;There are 100k students in med school each year. Room and board is about 100k per year. For $10B a year, med school could be free,&#8221; Cuban said recently on <a href="https://bsky.app/profile/mcuban.bsky.social/post/3ls5urzyfys2v">Bluesky</a>.
<h2 class="wp-block-heading">A Bold Proposal With Economic Upside</h2>
Cuban believes this kind of investment &#8220;would see a wholesale change in the profession, career paths and the cost of care.&#8221; He argues that high education costs force students to make financial decisions that limit their options and ultimately hurt the healthcare system.
Don't Miss:
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a></li>
</ul>
This isn&#8217;t a new idea for him. Back in December, Cuban floated a similar plan, saying the government could fund <a href="https://www.benzinga.com/news/24/12/42678209/free-medical-school-for-all-mark-cuban-says-its-doable-for-just-2-5-billion-a-year-is-it-an-expense-or-a-strategic-cost-saving-move">free medical school</a> for under $2.5 billion a year. At the time, Cuban estimated the cost by multiplying the number of students by average expenses, noting there are fewer than 25,000 medical students in the U.S. and average annual costs are typically below $100,000 per student.
He also suggested that private companies might be willing to cover students&#8217; education in exchange for post-graduate employment, especially as AI and other technologies reshape health care.
<h2 class="wp-block-heading">Pushback From Congress</h2>
Cuban's renewed comments came as the Senate passed a <a href="https://www.benzinga.com/news/politics/25/06/46161747/thom-tillis-pulls-out-of-2026-re-election-run-after-saying-he-cannot-support-trump-backed-one-big-beautiful-bill-president-calls-it-great-news">tax bill</a> on July 1 that includes, among other things, new limits on how much students can borrow for medical and other professional degrees. It is now before the House for final approval. The proposed cap is $200,000, well below the real cost of attending med school.
Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
<a href="https://store.aamc.org/medical-student-education-debt-costs-and-loan-repayment-fact-card-for-the-class-of-2024.html">According to</a> the Association of American Medical Colleges, the median cost for the class of 2025 is $286,454 at public institutions and $390,848 at private ones.
Many in the medical field say these changes could shut out low-income and first-generation students, push them toward private loans with worse terms, and worsen the doctor shortage, especially in rural and primary care settings.
&#8220;When they come into medical education, more times than not, they don&#8217;t have co-signers,&#8221; Burrell College of Osteopathic Medicine President John L. Hummer told <a href="https://www.politico.com/news/2025/06/21/republican-medical-student-loan-limits-00415741">Politico</a>.
Sen. Roger Marshall (R-KS), who earned his medical degree in 1987 when tuition was a fraction of today's cost, wasn&#8217;t sympathetic. "Anyone who is paying more than $100,000 to go to school is making a huge mistake," he told Politico.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation.&nbsp;</a>
<h2 class="wp-block-heading">A Strategic Investment</h2>
Cuban frames free medical education as a smart long-term investment. After all, more doctors could improve access to care and reduce delays, allowing illnesses to be caught and treated earlier, which would result in better health outcomes for many Americans.
In February 2024, that vision came to life in one corner of the country. Ruth Gottesman, widow of Warren Buffett's longtime associate David Gottesman, <a href="https://www.benzinga.com/news/24/02/37348692/ruth-gottesman-donates-1b-to-medical-school-how-warren-buffett-berkshire-hathaway-factor-into-this-i">donated $1 billion</a> to the Albert Einstein College of Medicine in New York City, making tuition free for all future students.
And a <a href="https://www.benzinga.com/personal-finance/24/07/39709599/billionaire-bloombergs-1-billion-gift-makes-medical-school-free-at-johns-hopkins-should-other-bi">$1 billion donation</a> from Michael Bloomberg to Johns Hopkins University in Baltimore removes financial barriers for medical students from families making less than $300,000 per year. Living expenses are also covered for those earning less than $175,000.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Mark Cuban Says Med School Should Be Free—'For $10B A Year, We Would See A Change In The Profession, Career Paths, And The Cost Of Care'

B of A Securities analyst Ruplu Bhattacharya maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and raises the price target from $100 to $110.

ROKU

B of A Securities Maintains Buy on Roku, Raises Price Target to $110

LQR House shares are trading higher after announcing that an importer has placed its third major purchase order from the company, totaling 176 cases of SWOL tequila.

BellRing Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) short percent of float has risen 11.86% since its last report. The company recently reported that it has 3.99 million shares sold short, which is 3.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>BellRing Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751562062_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BellRing Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing BellRing Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, BellRing Brands's peer group average for short interest as a percentage of float is 6.36%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

BRBR

Is the Market Bullish or Bearish on BellRing Brands?

Press Releases

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Comments

Precision BioSciences

Precision BioSciences (DTIL) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL